Table 1 Discovery cohort description
From: Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer
Variable | Group | N | % of cohort (%) |
|---|---|---|---|
Tumor type | Adrenal gland cancer | 4 | 0.1 |
Bladder cancer | 80 | 1.5 | |
Brain and nervous system cancer | 55 | 1.1 | |
Breast cancer | 487 | 9.3 | |
Cervical cancer | 49 | 0.9 | |
Colorectal cancer | 603 | 11.5 | |
Esophageal cancer | 159 | 3.0 | |
Head and neck cancer | 144 | 2.7 | |
Kidney and renal pelvis cancer | 42 | 0.8 | |
Liver and bile duct cancer | 81 | 1.5 | |
Lung cancer | 2264 | 43.1 | |
Melanoma | 129 | 2.5 | |
Mesothelioma | 19 | 0.4 | |
Ovarian cancer | 270 | 5.1 | |
Pancreatic cancer | 216 | 4.1 | |
Prostate cancer | 153 | 2.9 | |
Sarcoma | 192 | 3.7 | |
Stomach cancer | 101 | 1.9 | |
Testicular cancer | 4 | 0.1 | |
Thymic cancer | 11 | 0.2 | |
Thyroid cancer | 32 | 0.6 | |
Uterine cancer | 155 | 3.0 | |
Cancer type | Metastatic | 2381 | 45.4 |
Primary | 2819 | 53.7 | |
Recurrent | 45 | 0.9 | |
No data | 5 | 0.1 | |
All samples | 5250 | 100.0 | |